Q-omics provides the consensus-scored EXOC6B profile across patient tissues and cancer cell-line models. EXOC6B expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, EXOC6B is differentially expressed in 12, with the highest sampling consensus in HNSC. Additionally, EXOC6B RNA expression shows 21,573 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRC, HNSC, and GBM as cancer lineages where EXOC6B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for EXOC6B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes EXOC6B survival associations across molecular data types. EXOC6B RNA expression shows survival associations in the most cancer types (24), followed by mutation status (6) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible EXOC6B RNA expression–survival associations across cancer types. High EXOC6B expression shows unfavorable associations in OV, MESO, KICH and LIHC, but favorable associations in KIRC and SCLC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for EXOC6B RNA expression.
This table summarizes EXOC6B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 6. The strongest signals are observed in HNSC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for EXOC6B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. EXOC6B shows lower tumor expression in COAD and KICH and higher tumor expression in HNSC, LIHC, LUSC and BLCA. The HNSC box plot shows higher EXOC6B RNA expression in tumor versus normal tissue (log2 FC = +0.921, t-test p < 0.001).
This table shows molecular features associated with EXOC6B in patient tissues and cancer cell lines. In patient samples, EXOC6B shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, EXOC6B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and BLOOD_Lymphoma.
